A new Alzheimer’s drug, once worth billions, is headed for the trash

(By Damian Garde for STAT)

Axovant Sciences (AXON), 2017’s most talked-about biotech company, is abandoning the drug that made it famous after yet another clinical trial failure. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.